I think the price is the price of the ADHD disaster, it will change with RD success, and then alot more with a transaction with BP-I believe dramatically-$5. But the price is low because it burned alot of the available investment capital from microcap healthcare and hedge funds, the stock's main capital source for internal and external funds. The need for new products in BP is going to become more and more front and center-exciting new products ( molecules and classes of molecules in our case) at all stages that can remedy this are going to be rewarded.
News 
Market Data 
Discover 
